Sergey G. Zakharov

Sergey G. Zakharov

Auto-generated profile, based on publicly available information

Sergey G. Zakharov

M.F. Vladimirskiy Moscow regional research clinical Institute

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Oncohematology
Verified
Journal Article
Open access
PDF file
SZS. G. Zakharov
S. G. Zakharov
TMT. A. Mitina
T. A. Mitina
AZA. V. Zakharova
A. V. Zakharova
RVR. V. Vardanyan
R. V. Vardanyan
EKE. V. Kataeva
E. V. Kataeva
ЮЧЮ. Б. Черных
Ю. Б. Черных
Glucocorticosteroids (GCS) are the first-line treatment for idiopathic thrombocytopenic purpura (ITP). Despite their high efficacy in patients with newly diagnosed ITP, an adequate level of platelets remains after GCS withdrawal in only less than 20 % of patients. Additionally, GCS use is associated with an increased risk of different adverse reactions, including serious and life-threatening ones. Thrombopoietin receptor agonists represent a relatively new class of drugs for treating ITP as a second-line therapy. This paper reviews the risks of GCS pharmacotherapy, as well as the evidence supporting the use of thrombopoietin receptor agonists as both first-line and second-line treatment for patients with ITP.

10 August 2019 in Russian journal of hematology and transfusiology
Verified
Journal Article
Open access
AGA. K. Golenkov
A. K. Golenkov
ETE. V. Trifonova
E. V. Trifonova
EKE. V. Kataeva
E. V. Kataeva
TMT. A. Mitina
T. A. Mitina
LVL. L. Vusotskaya
L. L. Vusotskaya
SMS. A. Maryina
S. A. Maryina
Aim. To evaluate the concentration of immunoglobulin free light chains (FLC) in comparison with that of intact measurable paraproteins (PIg) in patients with relapsed/resistant multiple myeloma (RR MM) undergoing treatment with bortezomib.Materials and methods. A retrospective study included 15 patients with RR MM with intact measurable PIg. Following 6 cycles of bortezomib treatment, an evaluation of the treatment efficacy was performed using standard criteria and by analysing serum FLC of immunoglobulins (sFLC).Results. A partial response (PR) and small response was achieved in 4 and 5 patients, respectively. The stabilization of the disease was observed in 6 patients. No cases of complete response (CR) or stringent complete response (SCR) were recorded. On the basis of the data on the concentration of sFLC after treatment, all patients were divided into 2 groups: those with an abnormal (clonal) and normal κ/λ ratio. In 11 patients with a response lower than PR, sFLC κ/λ ratio was of a clonal nature, which corresponded to changes in the concentrations of intact PIg during treatment. In 4 cases with PR, the residual tumour was determined by the presence of intact PIg within the 32–45 % range under, however, a normal sFLC κ/λ ratio.Conclusion. Treatment with bortezomib affects all processes in MM with intact PIg, such as synthesis of FLC by tumour plasma cells, a decrease in the amount of circulating sFLC in blood and in the concentration of intact PIg. Normalization of sFLC κ/λ ratio under the achievement of PR could be considered as a prognostic factor in a favourable clinical outcome.

10 April 2019 in Oncohematology
Verified
Journal Article
Open access
PDF file
KBK. A. Belousov
K. A. Belousov
TMT. A. Mitina
T. A. Mitina
YCYu. Yu. Chuksina
Yu. Yu. Chuksina
AGA. K. Golenkov
A. K. Golenkov
EKE. V. Kataeva
E. V. Kataeva
ЮЧЮ. Б. Черных
Ю. Б. Черных
Objective: to study the efficacy and safety of the antitumor RVP program (lenalidomide, bortezomib, prednisone) as a first-line therapy in patients with multiple myeloma (MM). Materials and methods. A prospective study involved 39 patients with MM (15 women, 24 men), median age 61 years (30–76 years). All patients had Durie–Salmon stage III disease. According to the paraprotein isotype variant, 19 patients (48.7 %) had Gk myeloma, 8 (20.5 %) had Gλ, 4 (10.2 %) – Ak, 1 – Aλ, 1 – Dk, 1 – paraproteinemia Bens-Jones k and 1 – Bens-Jones λ, 2 – Dλ, and 2 patients – nonsecreting MM. The average level of plasma cells in the bone marrow was 31.7 % (0.8–80.0 %). In 14 (35.8 %) patients there were plasmacytomas of various localization (spine, cranial bones, clavicle, pleura). Nine (23.0 %) patients had renal failure, requiring the start of renal replacement therapy. The average Karnovsky index in the study group was 50 %. All patients received RVP therapy (lenalidomide 25 mg in 1–14 days, bortezomib 1.3 mg subcutaneously in 1, 4, 8, 11 days, prednisolone 60 mg/m2; the interval between courses was 42 days) as the first line therapy. Evaluation of therapy efficacy, characterized by overall survival, objective response rates (the number of complete, very good partial and partial remissions) was performed after 6 treatment courses. Results. The median follow-up was 15 months; the median of overall survival was not achieved. Objective antitumor response achieved in 29 (74.3 %) patients, including complete remissions in 3 (7.6 %), very good partial remissions – in 7 (17.9 %), partial remissions – in 19 (48.7 %) patients. In 2 out of 9 patients who received renal replacement therapy, independence from dialysis therapy was achieved. Cases of III–IV stage hematological and non-hematological toxicity in the study were not noted. Conclusion. The antitumor RVP program showed high efficacy and safety as a first-line therapy in a non-selective group of patients, including those with a complicated MM course.

2 April 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
SZS. G. Zakharov
S. G. Zakharov
TMT. A. Mitina
T. A. Mitina
AZA. V. Zakharova
A. V. Zakharova
OMO. P. Madzyara
O. P. Madzyara
IKI. N. Kontievskii
I. N. Kontievskii
ЮЧЮ. Ю. Чуксина
Ю. Ю. Чуксина
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by increased platelet destruction and decreased platelet production. The formation of antibodies to platelet and megakaryocyte glycoproteins plays a major role in the pathophysiology of ITP. All treatment strategies for ITP attempt to increase platelet count and reduce the risk of bleeding complications. Corticosteroids remain the most commonly used first-line therapy for ITP, but their long-term use is limited due to the development of severe complications. Today the new treatment methods including the use of thrombopoietin receptor agonists (TPO-RA) romiplostim, eltrombopag and avatrombopag with a number of advantages over standard therapy are of great interest. These drugs are recommended for use in the second-line therapy and show high efficacy in patients with ITP, particularly in real clinical practice. In most cases TPO-RA provide stable and long-term remission of the disease, allowing you to reduce or discontinue the use of glucocorticosteroids and avoid splenectomy. Many studies of the mechanism of action, efficacy and toxicity of TPO-RA have been performed. the research results significantly expand our knowledge about these agents. This review provides comparative data of the TPO-RA safety and the main aspects of their clinical use. The features of the new drug avatrombopag, recently approved for use in the Russian federation, are described. the overview presents the advantages and limitations of each drug, possible adverse events and methods for their control.

10 December 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
YCYu. Yu. Chuksina
Yu. Yu. Chuksina
SZS. G. Zakharov
S. G. Zakharov
TMT. A. Mitina
T. A. Mitina
AKA. N. Khmelevskaya
A. N. Khmelevskaya
ЮЧЮ. Ю. Чуксина
Ю. Ю. Чуксина
Background. The leading role in the control of the immune response and peripheral tolerance is played by T-regulatory cells, as well as costimulatory molecules C28 on T-lymphocytes, which are necessary for effective activation. While T-regulatory cells in immune thrombocytopenia (IT) are actively studied in order to find an effective influence on their functions, publications on the study of costimulation processes in this disease are quite rare. Given the pronounced immunosuppressive effect of glucocorticosteroids (GCS) used in the treatment of patients with IT, it seems particularly relevant to study the role of T-regulatory cells and the expression features of costimulatory C28 molecules on T-lymphocytes to expand our understanding of the disease pathogenesis and justify new approaches to treating patients in real clinical practice.Aim. To evaluate the clinical and prognostic significance of T-regulatory cells and C28 expression on peripheral blood T-lymphocytes in patients with newly diagnosed IT and resistant to GCS therapy.Materials and methods. The content of T-regulatory cells and C28 expression features on peripheral blood T-lymphocytes were studied by flow cytometry in 18 patients with newly diagnosed IT and 19 patients resistant to GCS therapy. Thirty healthy individuals were examined as a control group.Results. A significant (p ˂ 0.05) decrease in the content of classical T-regulatory cells (C4+C25+hiC127–) was revealed both in patients with newly diagnosed IT and in those resistant to GCS, while no significant differences were found in C8+C28– peripheral T-regulatory cells level in patients with IT of both groups compared to healthy individuals. In patients with IT of both groups, a significant increase in the proportion of T-helper (p 05; p ˂ 01, respectively) and cytotoxic C8+ (p ˂ 0.05; p ˂ 0.01, respectively) T-lymphocytes expressing C28 was found compared to normal values. The level of T-helper lymphocytes (C4+C28–) was 2 times higher in the group of patients with resistance to GCS compared to newly diagnosed IT patients, and 3.5 times higher compared to healthy individuals.Conclusion. T-regulatory cells and expression of C28 costimulatory molecules play an important role in the immunopathogenesis of IT. A significant increase in the content of the C4+C28null lymphocyte population (C4+C28–) in the peripheral blood of IT patients can be a prognostic criterion for GCS resistance, which may require a revision of the treatment strategy.

1 September 2024 in Oncohematology
Verified
Journal Article
Open access
PDF file
SZS. G. Zakharov
S. G. Zakharov
Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a decrease in platelet count, which often leads to bleeding. Evidence suggests that low platelet counts in ITP are the result of multiple factors, including impaired thrombocytopoiesis and changes in the immune response leading to platelet destruction. ITP is a heterogeneous disease with a course that is difficult to predict. In a significant number of cases, ITP becomes chronic, requiring long-term maintenance treatment, which leads to an increased risk of hemorrhagic complications and a decrease in quality of life. A deeper understanding ofthe etiology and pathogenesis ofthis disease makesit possible to identify potentialtherapeutic targets for the development of new effective treatments. This review summarizes recent advances in understanding the ITP pathophysiology, evaluating current therapeutic strategies and methods for predicting therapy response.